Loading clinical trials...
Loading clinical trials...
Randomized, Double-blind, Placebo-controlled, Multi-center Study of Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients of NSCLC With Brain Metastases of Driven Gene-negative and Not Received Systemic Chemotherapy
Conditions
Interventions
Camrelizumab
Placebo
+5 more
Start Date
March 5, 2021
Primary Completion Date
April 30, 2022
Completion Date
April 30, 2024
Last Updated
February 24, 2021
NCT07336732
NCT05568212
NCT06574347
NCT02448992
NCT06281964
NCT05904379
Lead Sponsor
Guangdong Association of Clinical Trials
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions